New Chief Medical Officer at Arvinas

Angela Shen brings extensive experience in clinical development, medical affairs and business development to the firm

Arvinas, a US biotechnology company based in New Haven, Connecticut, that is creating a new class of oncology drugs based on protein degradation, has hired Angela Shen as Chief Medical Officer.

Prior to joining Arvinas, Shen spent more than six years with Novartis Oncology. As a global clinical programe head, she helped launch the CTL019 (CART-19) Cell & Gene Therapy programme and built a clinical and operations team. As head of clinical evaluation for the Oncology Business Development group, she was involved in licensing in new compounds to strengthen the Novartis Oncology pipeline, including CTL019. Previously, Shen was a clinical lead at Novartis for the development of new oncology assets including panobinostat (Farydak) and inhibitors of the enzyme PI3-kinase.

At Exelixis, Shen was clinical lead for multiple drugs in early development, including cobimetinib (Cotellic), which was subsequently developed by Genentech and recently obtained FDA approval.

At Johnson & Johnson, she held a medical affairs role supporting Velcade, Doxil, Yondelis, and Procrit.

You may also like

Research & Development

Merck & Co collaborates with Arvinas on novel protein degradation technology

Multi-year agreement will focus on multiple disease targets across several therapeutic areas
Packaging

Innovating primary packaging for parenteral drugs: challenges and future directions

The new challenges brought about by the pandemic call for an increasingly scientific approach to the evolution of single packaging elements in order to anticipate the needs of new drug formulations and guarantee a more enhanced, measurable and stable level of performance
Regulatory

US Pharmacopeia details mass spectrometry guidelines to advance biologics impurity control

The new chapter aims to standardise the use of mass spectrometry-based analysis in the biopharmaceutical industry, which can be used to detect impurities in cell and gene therapies, antibodies and other biologics
You need to be a subscriber to read this article.
Click here to find out more.
Research & Development

Hybrid interferons: developing a novel drug class

With many hurdles to overcome, establishing a new drug candidate is a long process — particularly if you are a smaller biotech company with limited resources. These challenges can be further amplified if the candidate being developed is of an entirely novel drug class
Packaging

How pharma packaging manufacturers role is evolving: the case of extractables testing

As the pharmaceutical industry continues to grow and evolve, extractables testing is a critical component of the pharmaceutical industry's efforts to prioritise quality and safety, ensuring one of the key functions pharma containers are designed for, says Anna Malori, Head of Product Management at Bormioli Pharma
Distribution

2BScientific expands its life science product supply service to Europe with new German facility

The facility in Munich will serve the European market with life science products, including in vitro diagnostic (IVD) reagents, buffers, biomaterials and antibodies
Manufacturing

Anton Paar expands Litesizer DIA Series with new models

Introducing affordable and advanced solutions for particle analysis
Subscribe now